Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2012

01-01-2012 | Review Article

The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding

A Benefit-Risk Review

Authors: Dr Andrew M. Kaunitz, MD, Pirjo Inki

Published in: Drugs | Issue 2/2012

Login to get access

Abstract

Heavy menstrual bleeding (HMB) is a common problem in women of reproductive age and can cause irritation, inconvenience, self-consciousness and fear of social embarrassment. Our objective was to review and appraise literature identified from the MEDLINE and EMBASE databases to evaluate the clinical evidence and provide an update on the risks and benefits of using the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of HMB.
The LNG-IUS consistently reduces menstrual blood loss (MBL) in women with HMB, including those with underlying uterine pathology or bleeding disorders. The available data suggest that it reduces MBL to a greater extent than other medical therapies, including combined oral contraceptives, oral progestogens (both short- or long-cycle regimens), tranexamic acid and oral mefenamic acid. In addition, the LNG-IUS and endometrial ablation appear to reduce MBL to a similar extent. The adverse effects reported with the LNG-IUS in women with HMB are similar to those typically observed in women using the system for contraception. Uterine perforations were not reported in any of the studies reviewed, but expulsion rates may be higher than in the general population of LNG-IUS users. Overall, the LNG-IUS has a positive effect on most quality-of-life domains, at least comparable to those achieved with hysterectomy or endometrial ablation, and is consistently a cost-effective option across a variety of countries and settings.
In conclusion, the LNG-IUS is an effective treatment option for women with HMB, including those with underlying organic pathology or bleeding disorders.
Literature
1.
Matteson KA, Clark MA. Questioning our questions: do frequently asked questions adequately cover the aspects of women’s lives most affected by abnormal uterine bleeding? Opinions of women with abnormal uterine bleeding participating in focus group discussions. Women Health 2010 Mar; 50(2): 195–211PubMedCentralPubMedCrossRef
2.
3.
Moragianni VA, Somkuti SG. Profound hypothyroidism-induced acute menorrhagia resulting in life-threatening anemia. Obstet Gynecol 2007 Aug; 110 (2 Pt 2): 515–7PubMedCrossRef
4.
Gutierrez G, Brotherton J. Management of severe anemia secondary to menorrhagia in a Jehovah’s Witness: a case report and treatment algorithm. Am J Obstet Gynecol 2011 Aug; 205(2): e5–8PubMedCrossRef
5.
Hashem B, Dillard TA. A 44-year-old Jehovah’s Witness with life-threatening anemia from uterine bleeding. Chest 2004 Mar; 125(3): 1151–4PubMedCrossRef
6.
Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss: a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45(3): 320–51PubMedCrossRef
7.
Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008 Jan; 14(1): 15–20PubMed
8.
Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002 Oct; 100(4): 683–7PubMedCrossRef
9.
Cote I, Jacobs P, Cumming DC. Use of health services associated with increased menstrual loss in the United States. Am J Obstet Gynecol 2003 Feb; 188(2): 343–8PubMedCrossRef
10.
Yusuf F, Siedlecky S. Hysterectomy and endometrial ablation in New South Wales, 1981 to 1999–2000. Aust N Z J Obstet Gynaecol 2004 Apr; 44(2): 124–30PubMedCrossRef
11.
Wu JM, Wechter ME, Geller EJ, et al. Hysterectomy rates in the United States, 2003. Obstet Gynecol 2007 Nov; 110(5): 1091–5PubMedCrossRef
12.
Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011 Apr; 113(1): 3–13PubMedCrossRef
13.
Critchley HO, Warner P, Lee AJ, et al. Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Technol Assess 2004 Sep; 8(34): iii–iv, 1–139PubMed
14.
Vercellini P, Cortesi I, De Giorgi O, et al. Transvaginal ultrasonography versus uterine needle biopsy in the diagnosis of diffuse adenomyosis. Hum Reprod 1998 Oct; 13(10): 2884–7PubMedCrossRef
15.
Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography in the diagnosis of diffuse adenomyosis. Fertil Steril 1992 Jul; 58(1): 94–7PubMed
16.
Clevenger-Hoeft M, Syrop CH, Stovall DW, et al. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol 1999 Oct; 94(4): 516–20PubMedCrossRef
17.
Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001 Apr; 97(4): 630–6PubMedCrossRef
18.
Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998 Feb 14; 351(9101): 485–9PubMedCrossRef
19.
Philipp CS, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005 Jan; 105(1): 61–6PubMedCrossRef
20.
Bevan JA, Maloney KW, Hillery CA, et al. Bleeding disorders: a common cause of menorrhagia in adolescents. J Pediatr 2001 Jun; 138(6): 856–61PubMedCrossRef
21.
Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994 Jan; 49(1): 56–72PubMedCrossRef
22.
Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996 Oct; 54(4): 201–8PubMedCrossRef
23.
Gemzell-Danielsson K, Inki P, Boubli L, et al. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS): a multicentre prospective study. Hum Reprod 2010 Feb; 25(2): 354–9PubMedCrossRef
24.
Lewis RA, Taylor D, Natavio MF, et al. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception 2010 Dec; 82(6): 491–6PubMedCrossRef
25.
Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000 Aug; 15 Suppl. 3: 162–72PubMedCrossRef
26.
Zhu PD, Luo HZ, Xu RH, et al. The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium: a comparative study of three IUDs. A morphometric study of 96 cases. Contraception 1989 Oct; 40(4): 425–38
27.
Pakarinen PI, Lahteenmaki P, Lehtonen E, et al. The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel. Hum Reprod 1998 Jul; 13(7): 1846–53PubMedCrossRef
28.
Fraser IS, Critchley HO, Munro MG, et al. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 2007 Mar; 22(3): 635–43PubMedCrossRef
29.
Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007 Mar; 87(3): 466–76PubMedCrossRef
30.
Zakherah MS, Sayed GH, El-Nashar SA, et al. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest 2011; 71(4): 281–4PubMedCrossRef
31.
Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG 2000 Mar; 107(3): 320–2PubMedCrossRef
32.
Abdel Malak K, Shawki O. Management of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Gynecol Surg 2006; 3(4): 275–80CrossRef
33.
Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol 2003 May 1; 108(1): 72–4PubMedCrossRef
34.
Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG 2006 Mar; 113(3): 257–63PubMedCrossRef
35.
Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997 Aug; 90(2): 257–63PubMedCrossRef
36.
de Souza SS, Camargos AF, de Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception 2010 Mar; 81(3): 226–31PubMedCrossRef
37.
Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 2009 Apr; 31(4): 340–7PubMed
38.
Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001 Jan 27; 357(9252): 273–7PubMedCrossRef
39.
Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998 Jun; 105(6): 592–8PubMedCrossRef
40.
Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010 Sep; 116(3): 625–32PubMedCrossRef
41.
Kucuk T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008; 35(1): 57–60PubMed
42.
Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol 2004 Dec; 104(6): 1314–21PubMedCrossRef
43.
Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. Br J Obstet Gynaecol 2005 Aug; 112(8): 1121–5CrossRef
44.
Shaaban MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011 Jan; 83(1): 48–54PubMedCrossRef
45.
Shaw RW, Symonds IM, Tamizian O, et al. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol 2007 Aug; 47(4): 335–40PubMedCrossRef
46.
Soysal M, Soysal S, Ozer S. A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol 2002 Apr; 124(4): 213–9PubMedCrossRef
47.
Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001 Aug; 76(2): 304–9PubMedCrossRef
48.
Kittelsen N, Istre O. A randomized study comparing levonorgestrel intrauterine system (LNG IUS) and transcervical resection of the endometrium (TCRE) in the treatment of menorrhagia: preliminary results. Gynaecol Endosc 1998; 7(2): 61–5CrossRef
49.
Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990 Aug; 97(8): 690–4PubMedCrossRef
50.
Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997 May; 104(5): 614–6PubMedCrossRef
51.
Gorgen H, Api M, Akca A, et al. Use of the levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet 2009 Jun; 279(6): 835–40PubMedCrossRef
52.
Gupta B, Mittal S, Misra R, et al. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet 2006 Dec; 95(3): 261–6
53.
Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet 2007 Jun; 97(3): 190–4PubMedCrossRef
54.
Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991 Mar; 164(3): 879–83PubMedCrossRef
55.
Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995 Apr; 51(4): 231–5PubMedCrossRef
56.
Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003 Apr; 79(4): 963–9PubMedCrossRef
57.
Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004 Mar 24; 291(12): 1456–63PubMedCrossRef
58.
Inki P, Hurskainen R, Palo P, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol 2002 Oct; 20(4): 381–5CrossRef
59.
Hurskainen R, Paavonen J. Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding. Curr Opin Obstet Gynecol 2004 Dec; 16(6): 487–90PubMedCrossRef
60.
Halmesmaki KH, Hurskainen RA, Cacciatore B, et al. Effect of hysterectomy or LNG-IUS on serum inhibin B levels and ovarian blood flow. Maturitas 2007 Jul 20; 57(3): 279–85PubMedCrossRef
61.
Halmesmaki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod 2004 Feb; 19(2): 378–82PubMedCrossRef
62.
Halmesmaki KH, Paavonen JA, Tuppurainen MT, et al. Randomized controlled trial of the effect of hysterectomy or LNG-IUS on bone mineral density: a five-year follow-up. Therapy 2006; 3(4): 509–15CrossRef
63.
Heinemann K, Assman A, Dinger J, et al. Intrauterine devices and the risk of uterine perforations: interim results from the EURAS-IUD study. Poster presented at the American Congress of Obstetricians and Gynecologists (ACOG) 58th Annual Clinical Meeting; 2010 May 15–19; San Francisco (CA)
64.
Mansour D. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception. Epub 2011 Sep 19
65.
Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007 Mar; 75(3): 193–8PubMedCrossRef
66.
Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: nocebo or noise? Contraception 2011 Jan; 83(1): 5–9PubMedCrossRef
67.
Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007 May; 75(5): 344–54PubMedCrossRef
68.
Bergendal A, Odlind V, Persson I, et al. Limited knowledge on progestogen-only contraception and risk of venous thromboembolism. Acta Obstet Gynecol Scand 2009; 88(3): 261–6PubMedCrossRef
69.
Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009 May; 113(5): 1104–16PubMedCrossRef
70.
Gurtcheff SE, Sharp HT. Complications associated with global endometrial ablation: the utility of the MAUDE database. Obstet Gynecol 2003 Dec; 102(6): 1278–82PubMedCrossRef
71.
Della Badia C, Nyirjesy P, Atogho A. Endometrial ablation devices: review of a manufacturer and user facility device experience database. J Minim Invasive Gynecol 2007 Jul–Aug; 14(4): 436–41PubMedCrossRef
72.
Lo JS, Pickersgill A. Pregnancy after endometrial ablation: English literature review and case report. J Minim Invasive Gynecol 2006 Mar–Apr; 13(2): 88–91PubMedCrossRef
73.
Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003 May; 79(5): 1194–8PubMedCrossRef
74.
Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003 Apr; 67(4): 277–80PubMedCrossRef
75.
Murat Naki M, Tekcan C, Ozcan N, et al. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril 2010 Jun; 94(1): 371–4PubMedCrossRef
76.
Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet 2010 Feb; 112(2): 126–30PubMedCrossRef
77.
Shawki O, El-Sherbiny W, Saber W, et al. Treatment of heavy menstrual bleeding associated with uterine leiomyoma with the levonorgestrel-releasing intrauterine system. Gynecol Surg 2009; 6(4): 331–7CrossRef
78.
Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005; 59(1): 29–35PubMedCrossRef
79.
Levens ED, Wesley R, Premkumar A, et al. Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for research and clinical care. Am J Obstet Gynecol 2009 May; 200(5): 537 e1-7PubMedCentralPubMedCrossRef
80.
Meredith SM, Sanchez-Ramos L, Kaunitz AM. Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis. Am J Obstet Gynecol 2009 Jul; 201(1): 107 e1-6PubMedCrossRef
81.
Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997 Sep; 68(3): 426–9PubMedCrossRef
82.
Bragheto AM, Caserta N, Bahamondes L, et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007 Sep; 76(3): 195–9PubMedCrossRef
83.
Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011 Feb; 95(2): 497–502PubMedCrossRef
84.
Maia Jr H, Maltez A, Coelho G, et al. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc 2003 Nov; 10(4): 512–6PubMedCrossRef
85.
Peng FS, Wu MY, Yang JH, et al. Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method. Taiwan J Obstet Gynecol 2010 Jun; 49(2): 160–4PubMedCrossRef
86.
Kadir RA, Chi C. Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy. Contraception 2007 Jun; 75 (6 Suppl.): S123–9PubMedCrossRef
87.
Kingman CE, Kadir RA, Lee CA, et al. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br J Obstet Gynaecol 2004 Dec; 111(12): 1425–8CrossRef
88.
Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 2011 Mar; 83(3): 242–7PubMedCrossRef
89.
Vilos GA, Tureanu V, Garcia M, et al. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy. J Minim Invasive Gynecol 2009 Jul–Aug; 16(4): 480–4PubMedCrossRef
90.
Kilic S, Yuksel B, Doganay M, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception 2009 Aug; 80(2): 152–7PubMedCrossRef
91.
Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008 Sep; 90(3): 673–7PubMedCrossRef
92.
Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus 2006; 15(12): 877–80PubMedCrossRef
93.
Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 2005 Oct; 193(4): 1361–3PubMedCrossRef
94.
Vilos GA, Marks J, Tureanu V, et al. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011 Jan–Feb; 18(1): 75–80PubMedCrossRef
95.
Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet 2011 Mar; 112(3): 171–8PubMedCrossRef
96.
Middleton LJ, Champaneria R, Daniels JP, et al. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients. BMJ 2010; 341: c3929PubMedCentralPubMedCrossRef
97.
Halmesmaki K, Hurskainen R, Teperi J, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. Br J Obstet Gynaecol 2007 May; 114(5): 563–8CrossRef
98.
Lete I, del Carme Cuesta M, Marin JM, et al. Acceptability of the levonorgestrel intrauterine system in the long-term treatment of heavy menstrual bleeding: how many women choose to use a second device? Eur J Obstet Gynecol Reprod Biol 2010 Jan; 154(1): 67–70PubMedCrossRef
99.
Lete I, Cristobal I, Febrer L, et al. Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain. Eur J Obstet Gynecol Reprod Biol 2011 Jan; 154(1): 71–80PubMedCrossRef
100.
Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ 2011; 342: d2202PubMedCentralPubMedCrossRef
101.
Bhattacharya S, Middleton LJ, Tsourapas A, et al. Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess 2011 Apr; 15(19): iii–xvi, 1–252PubMed
Metadata
Title
The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding
A Benefit-Risk Review
Authors
Dr Andrew M. Kaunitz, MD
Pirjo Inki
Publication date
01-01-2012
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2012
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11598960-000000000-00000

Other articles of this Issue 2/2012

Drugs 2/2012 Go to the issue

Adis Drug Evaluation

Repaglinide

Review Article

Are Proton Pump Inhibitors Safe during Pregnancy and Lactation?

Review Article

Pharmacotherapy for Breakthrough Cancer Pain

Erratum

Erratum to Pharmacotherapy for breakthrough cancer pain

Erratum

Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer

Adis Drug Evaluation

Saxagliptin